Malaria vaccines

Gavi opened funding windows for malaria vaccines in late 2022 to support the introduction and scale-up of the vaccines. Countries may request Gavi support to introduce the malaria vaccine using a 4- or 5-dose schedule, depending on local epidemiology, in areas with moderate or high P. falciparum malaria transmission. Requests for Gavi support for malaria vaccine in areas of low transmission may be considered based on a strong programmatic justification and subnational tailoring of malaria control interventions ^{Go to footnote 11}. 

In the 6.0 strategic cycle starting 2026, Gavi’s scope of support is limited to the vaccine requirements for up to 70% of countries’ areas of moderate and high P. falciparum malaria transmission ^{Go to footnote 22}. WHO has developed guidance for countries considering where to introduce the malaria vaccine ^{Go to footnote 33}, according to national plans and priorities – as well as funding available. 

Gavi supports WHO recommended and pre-qualified vaccines (RTS,S/AS01 and R21/Matrix-M). Countries approved to introduce malaria vaccines are matched with one of the two products. Switches from one product to another will be allowed on an exceptional basis with defined criteria, aligned with Gavi policy ^{Go to footnote 44}.